These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522 [TBL] [Abstract][Full Text] [Related]
26. Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria. Weaver K; Stallworth K; Blakely KK Nurs Womens Health; 2020 Oct; 24(5):377-382. PubMed ID: 32890463 [TBL] [Abstract][Full Text] [Related]
27. Microbiology of airway disease in a cohort of patients with cystic fibrosis. Lambiase A; Raia V; Del Pezzo M; Sepe A; Carnovale V; Rossano F BMC Infect Dis; 2006 Jan; 6():4. PubMed ID: 16405721 [TBL] [Abstract][Full Text] [Related]
28. Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. Rolston KVI; Gerges B; Shelburne S; Aitken SL; Raad I; Prince RA Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071053 [TBL] [Abstract][Full Text] [Related]
29. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients. Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802 [No Abstract] [Full Text] [Related]
31. Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients. Díez-Aguilar M; Ekkelenkamp M; Morosini MI; Merino I; de Dios Caballero J; Jones M; van Westreenen M; Tunney MM; Cantón R; Fluit AC Int J Antimicrob Agents; 2019 Jan; 53(1):84-88. PubMed ID: 30240837 [TBL] [Abstract][Full Text] [Related]
32. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa. Vickery SB; McClain D; Wargo KA Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066 [TBL] [Abstract][Full Text] [Related]
34. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343 [TBL] [Abstract][Full Text] [Related]
35. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship. Aoki T; Yoshizawa H; Yamawaki K; Yokoo K; Sato J; Hisakawa S; Hasegawa Y; Kusano H; Sano M; Sugimoto H; Nishitani Y; Sato T; Tsuji M; Nakamura R; Nishikawa T; Yamano Y Eur J Med Chem; 2018 Jul; 155():847-868. PubMed ID: 29960205 [TBL] [Abstract][Full Text] [Related]
36. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]